Alignment Healthcare, Inc.

Alignment Healthcare, Inc. (ALHC) Market Cap

Alignment Healthcare, Inc. has a market capitalization of —.

No quote data available.

CEO: John E. Kao

Sector: Healthcare

Industry: Medical - Healthcare Plans

IPO Date: 2021-03-26

Website: https://www.alignmenthealth.com

Alignment Healthcare, Inc. (ALHC) - Company Information

Market Cap: -|Sector: Healthcare

Company Profile

Alignment Healthcare, Inc. is a technology-driven Medicare Advantage provider operating a healthcare platform focused squarely on the consumer. This organization delivers personalized medical services across the United States, primarily for elderly individuals and others requiring specific support, leveraging its suite of Medicare Advantage plans. The company directly owns and operates Medicare Advantage programs in California, North Carolina, and Nevada. Beyond its proprietary offerings, it also orchestrates and furnishes essential healthcare services—including professional, institutional, and supplementary care—for beneficiaries of select plans from unrelated Medicare Advantage Health Maintenance Organizations. Established in 2013, Alignment Healthcare maintains its corporate base in Orange, California.

Analyst Sentiment

81%
Strong Buy

From 14 Active Polls

1Y Forecast: $20.00

â–Č +0.0% Potential Upside

Consensus Target Metrics

Low Bound

$16

Median

$22

High Bound

$22

Average

$20

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$20.00
â–Č +34.68% Upside
Low Target
$16.00
8% Risk
Median Target
$22.00
48% Mid
High Target
$22.00
48% Max

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

Sentiment volume allocation data unavailable.

Historical valuation matrix unavailable.

📘 Full Research Report

â„č

AI-Generated Research: This report is for informational purposes only.

📘 ALIGNMENT HEALTHCARE INC (ALHC) — Investment Overview

đŸ§© Business Model Overview

Alignment Healthcare operates a home-based care and care-management delivery model designed to serve seniors enrolled in Medicare Advantage plans. The value chain centers on: (1) contracting with payers/plan sponsors to deliver care under value-based arrangements, (2) deploying multidisciplinary care teams in member homes and care settings, and (3) coordinating clinical pathways across chronic conditions and post-acute episodes to reduce avoidable utilization while meeting quality requirements.

This creates a tightly managed operating loop: member identification and risk stratification → personalized care plans → ongoing in-home monitoring and care coordination → performance measurement against quality and utilization benchmarks → incentive economics tied to outcomes and costs.

💰 Revenue Streams & Monetisation Model

Revenue is typically structured around risk-adjusted, recurring economics (often described as per-member-per-month style consideration) combined with incentive components tied to quality, satisfaction, and/or shared savings under payer contracts. The business also benefits from a delivery model that can convert “care intensity” into measurable reductions in avoidable utilization.

Key margin drivers include:

  • Medical cost trend and utilization management: reducing avoidable admissions, emergency utilization, and duplicative services.
  • Care delivery productivity: scaling care team capacity while maintaining outcomes and compliance.
  • Contract quality and performance incentives: the degree to which contracts include measurable quality outcomes and shared-savings mechanics.

🧠 Competitive Advantages & Market Positioning

Alignment’s moat is primarily an integrated delivery ecosystem with operational know-how in risk-bearing care management. Competitors can replicate components (telehealth, care coordination, home visits), but replicating the full system—clinical workflows, member engagement cadence, utilization pathways, and payer performance reporting—requires time, staffing depth, and contracting experience.

  • Integrated ecosystem & execution barriers: a coordinated model that links clinician teams, care plans, and performance measurement in a consistent operating cadence. This raises the practical barriers to entry for new entrants.
  • High switching costs for payer contracting: payers incur measurable transition and performance risks when swapping providers, especially when contracts tie reimbursement to utilization and quality outcomes. Provider “replacement” involves operational onboarding, data/process integration, and performance ramp.
  • Operational learning curve: outcomes improve when care teams build repeatable playbooks for common chronic and post-acute trajectories, strengthening cost and quality discipline over time.

Competitive benchmarking (primary peers):

  • Clover Health: a Medicare Advantage–oriented platform with a heavier emphasis on analytics and plan-level capabilities. Alignment focuses more directly on hands-on, home-based care delivery under payer arrangements.
  • Amedisys: home health and hospice services provider with broad geographic reach. Alignment’s differentiation is its value-based, care-management integration rather than primarily fee-for-service provider economics.
  • Encompass Health: post-acute and rehabilitation provider. Alignment emphasizes upstream chronic care and care coordination to influence utilization patterns earlier in the care continuum.

Net: while peer competition exists across home care, post-acute, and Medicare Advantage enablement, Alignment’s positioning is best understood as a payers-facing, integrated care-management operator rather than a pure-play home health agency or purely a plan-analytics vendor.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, growth is supported by structural demand for better chronic disease management and a continued shift toward value-based care. Primary drivers include:

  • Medicare Advantage penetration: as enrollment expands, so does demand for provider partners capable of managing utilization and maintaining quality metrics.
  • Aging demographics and rising chronic conditions: increasing need for coordinated care that reduces avoidable utilization and improves member outcomes.
  • Value-based reimbursement expansion: payers seek partners with operational capability to manage medical cost trend while meeting performance targets.
  • Care model migration to home and hybrid settings: the delivery of care in member homes and coordinated settings remains a scalable approach to reach medically complex populations.
  • Contract breadth and contract durability: multi-year payer relationships can translate into compounding operational scale, improving unit economics when performance is sustained.

⚠ Risk Factors to Monitor

  • Medical cost volatility: risk-bearing economics can be pressured by higher-than-expected utilization, acuity mix changes, or imperfect risk adjustment.
  • Quality and compliance risk: performance outcomes tied to contracts can be affected by documentation, care plan adherence, and patient engagement variability.
  • Regulatory reimbursement changes: changes to Medicare Advantage rules, risk adjustment methodologies, or quality program scoring can alter contract economics.
  • Staffing and operational execution: sustaining clinician capacity, training, and care team retention is critical in home-based models.
  • Payer concentration and contracting dynamics: contract renewals, pricing terms, and incentive design can materially impact revenue trajectory.
  • Competitive pressure: large health systems and vertically integrated payers may expand provider networks, increasing acquisition costs and pressuring contract terms.

📊 Valuation & Market View

The market typically values healthcare services and value-based care platforms through revenue quality and margin durability rather than simple growth alone. Common valuation lenses include:

  • P/S for revenue scale when growth is expected to persist and economics are improving.
  • EV/EBITDA or operating leverage metrics as profitability becomes more visible and medical cost trends stabilize.
  • Unit economics focus: medical cost ratio trend, care management productivity, and the trajectory of incentive earnings.
  • Contract signal: payer relationship quality, renewal cadence, and the balance between fixed economics and performance-linked incentives.

Key drivers that move valuation in this sector tend to be consistent contract performance, improving operating leverage, and demonstrated ability to manage utilization while meeting quality standards.

🔍 Investment Takeaway

Alignment Healthcare presents a long-term investment case built on an integrated, value-based home care delivery ecosystem that can create practical switching costs for payers and an execution-driven barrier to entry. The core thesis depends on sustained performance: controlling medical cost trend, maintaining quality and compliance under contract incentives, and scaling care operations without degrading outcomes.


⚠ AI-generated — informational only. Validate using filings before investing.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-06-30

"ALHC reported Q2 2026 revenue of $1.336B and net income of $36.6M (EPS $0.17). YoY, revenue rose 31.6% (vs. $1.015B in Q2’25) and net income more than doubled (+133.6%; $36.6M vs. $15.7M). QoQ, revenue grew 8.2% (from $1.235B in Q1 2026), while net income surged 220% (from $11.4M). Profitability improved versus prior quarters: gross margin turned negative in Q2 2026 (-10.8%) after being positive in Q1 2026 (11.7%), but operating margin rebounded to 3.2% (from 1.3% in Q1) and net margin increased to 2.7% (from 0.9%). Cash flow quality weakened sequentially: operating cash flow was -$17.3M in Q2 (vs. +$128.7M in Q1) driven by working capital outflows (-$94.8M). Free cash flow was -$10.0M (down from +$121.3M in Q1). The balance sheet remains highly liquid: cash and equivalents were $693M with total assets of $1.279B; equity increased to $265M (from $207M). There is no dividend, and buybacks are not shown. Total shareholder return is supported by price momentum: the stock is up 8.9% over 1Y (not >20%), and dividends/buybacks appear minimal, implying value creation is primarily earnings/expectations-driven. Street targets (consensus ~$20) suggest the shares trade slightly above consensus."

Revenue Growth

Good

Q2’26 revenue rose 8.2% QoQ and 31.6% YoY, indicating strong top-line momentum.

Profitability

Fair

Net margin improved to 2.7% (from 0.9% QoQ) and EPS increased YoY; however gross margin swung negative in Q2 (-10.8%) before stabilizing at the operating/net levels.

Cash Flow Quality

Caution

Operating cash flow fell to -$17.3M QoQ (from +$128.7M) with working-capital drag; free cash flow turned negative (-$10.0M). No dividend support.

Leverage & Balance Sheet

Positive

Liquidity remains strong (cash ~$693M). Net debt is negative (net cash position) and total equity increased QoQ to $265M.

Shareholder Returns

Neutral

No dividends reported and no buybacks shown; total return relies on price performance. 1Y gain is 8.9% (below strong momentum threshold).

Analyst Sentiment & Valuation

Fair

Consensus price target (~$20) is below the current price ($21.22), suggesting slightly cautious upside versus expectations.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

ALHC reported strong Q2 2026 execution on both growth and margin. Membership rose 31% YoY to 294k, supporting $1.3B revenue (+32% YoY). Adjusted MBR improved ~40 bps to 86.3% (lowest as a public company), while SG&A as a % of revenue improved 20 bps and adjusted EBITDA margin expanded ~60 bps to 5.1%. Management reiterated embedded earnings leverage: existing-member embedded gross profit potential rose to ~$880M and midpoint full-year guidance already aligns above earlier early-2025 disclosures. The key near-term swing factor is deliberate back-half investment timing—management guided that ~30% of FY adjusted EBITDA will come from H2 (down from 40% last year) and expects seasonally higher MBR in Q3 due to earlier clinical hiring and heavier investment weighting. Analysts focused on Q3 investment cadence, MLR normalization around the sweep and reserves, and Part D/new-member mix seasonality.

AI IconGrowth Catalysts

  • AVA Care Anywhere clinical teams driving member engagement with visibility into member acuity over 6 months
  • Deployment of newest AVA AI powered stratification model predicting the 10% of members who account for nearly 70% of hospital admissions over the next 30 days
  • Disease state registries supporting proactive engagement and clinical operating model durability

Business Development

    AI IconFinancial Highlights

    • Q2 revenue $1.3B (+32% YoY); membership 294k (+31% YoY)
    • Adjusted gross profit $183M; adjusted MBR 86.3% improved ~40 bps YoY (Q2 lowest MBR as a public company)
    • Adjusted MBR excluding final sweep pickup was 86.7%, favorable to midpoint of guidance range
    • Adjusted SG&A $115M; SG&A as % of revenue 8.6% improved 20 bps YoY and beat implied guidance midpoint by 40 bps
    • Q2 adjusted EBITDA $68M (+48% YoY); adjusted EBITDA margin 5.1% (+~60 bps YoY)
    • First-half adjusted EBITDA $106M (+60% YoY), on track vs full-year guidance midpoint $154M
    • Cash: $702M in cash/cash equivalents/short-term investments at quarter end; first-half operating cash flow $111M
    • Funded leverage ratio improved to 2.2x trailing 12-month EBITDA
    • Q3 guide: membership 296k–298k; revenue $1.30B–$1.32B; adjusted gross profit $148M–$158M; adjusted EBITDA $20M–$30M
    • FY 2026 guide: membership 298k–1 million (range truncated in transcript); revenue $5.20B–$5.23B (raised toward ~5.2B midpoint reflecting +32% YoY); adjusted gross profit $630M–$650M (low end +$10M raised); adjusted EBITDA $145M–$163M (low end +$7M raised)

    AI IconCapital Funding

      AI IconStrategy & Ops

      • Back half investment plan: automation of back-office processes and greater economies of scale, with partial reinvestment of savings into market expansion, branding, and deeper AI capabilities
      • Q3 investment timing: additional double-digit million investments across clinical operations and SG&A, with weighting higher in Q3
      • Clinical operations investments in Q3 include AVA Care Anywhere and earlier ramp of clinical hiring for new market growth and expansion
      • SG&A timing shift: greater portion of FY SG&A incurred in Q3 vs prior years due to investment timing
      • Operational model centralization approach: building end-to-end competency to manage risk across contracting types (globally capped, delegated shared-risk, de-delegated) to expand ex-California
      • AI and automation targeted for administrative/back-end functions including MRA and SARS reconciliation; nurse workflow automation referenced via “chart prep”

      AI IconMarket Outlook

      • FY 2026 seasonality: midpoint expects ~30% of full-year adjusted EBITDA generated in H2 vs ~40% in prior year, driven partly by flatter Part D MBR slope and third-quarter clinical operations investments
      • Full-year embedded earnings commentary: embedded gross profit potential of existing membership grown to ~$880M (vs ~$600M opportunity disclosed in early 2025)

      AI IconRisks & Headwinds

      • MBR seasonality and mix risk: Q3 guidance implies seasonally higher MBR vs prior year due to earlier clinical hiring and clinical investments
      • Part D behavior: flatter slope vs last year but still sensitive to IRA-related utilization dynamics
      • Regulatory/contracting risk: uncertainty around CMS/OMB rulemaking for 2028 technical rules; participants cited lack of visibility and possible influence from SARS-related items
      • Competitive dynamics: management expects a mixed industry; 2–3 players may become more aggressive in 2027, increasing bid margin pressure
      • Stars/bonus regulatory and legal uncertainty: management stated regulatory/legal footing for Stars is “shaky,” influenced by competitor litigation outcomes

      Q&A: Analyst Interest

      • Q3 guide investments timing: Management explained two drivers—seasonality and deliberate investment cadence. They described MBR impact from clinical operations (AVA Care Anywhere and preparations for new market growth) and SG&A buildout for 2027 bids (automation/AI). They estimated additional “double digit million” investments in H2, heavier in Q3, but affirmed delivery of 2026 commitments.
      • Core MLR mechanics excluding one-time items: Management addressed the new-member final sweep and prior period reserve. They said the sweep was smaller than prior year largely due to V28 effects. They also stated they bolstered reserves by ~$6M after reviewing 2025 claim development; 2025 unfavorable was unrelated to the prior quarter’s January 2026 issue.
      • MBR seasonality + new member mix drivers: Management attributed Q3 Part D differences to a flatter H1-to-H2 slope versus last year, consistent with post-IRA behavior. For new member mix, they cited “more acuity” in the new-member mix year-over-year, creating additional MBR pressure, with clinical infrastructure investments identified as a key offsetting factor.

      Sentiment: POSITIVE

      Note: This summary was synthesized by AI from the ALHC Q2 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

      Loading financial data and tables...
      © 2026 Stock Market Info — Alignment Healthcare, Inc. (ALHC) Financial Profile